GLS — Glenmark Life Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Glenmark Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,864	15,373	18,852	21,232	21,612
Cost of Revenue
Gross Profit	5,341	8,469	9,797	10,803	11,471
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,506	10,931	13,231	15,440	15,603
Operating Profit	2,358	4,442	5,621	5,792	6,009
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,283	4,211	4,709	5,649	6,286
Provision for Income Taxes
Net Income After Taxes	1,956	3,131	3,516	4,187	4,670
Net Income Before Extraordinary Items
Net Income	1,956	3,131	3,516	4,187	4,670
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,956	3,131	3,516	4,187	4,670
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	16	25.6	28.7	35.7	38.4
Dividends per Share